| Document |
Document Title |
|
WO/2010/065671A2 |
Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VE...
|
|
WO/2010/063080A1 |
Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolised to a biologically active agent; and X is selected from the group consisting of R, or up to three R moieties attache...
|
|
WO/2010/065787A2 |
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention...
|
|
WO/2010/065852A1 |
This invention provides for novel antiparasitic and pesticidal derivatives of avermectin and milbemycin compounds in which two avermectin or milbemycin members are linked together by a chemical linker. The resulting compounds may be used...
|
|
WO/2010/065662A2 |
Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucl...
|
|
WO/2010/065444A1 |
The invention describes a cytotoxic composition containing a drug combination targeting two or more functional elements in pancreatic cancer cells, the functional elements comprising EGFR or Src and Stat3 or Jaks. Preferred drugs in the ...
|
|
WO/2010/062404A2 |
This invention relates to synthesis of novel -N-FMOC protected nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N...
|
|
WO/2010/061402A2 |
The present invention direct to an improved process for the preparation of the compound 5-deoxy -2, 3-O-isopyridene -N-[(pentyloxy) carbonyl]-5- fluorocystidine of the formula (I).
|
|
WO/2010/057185A1 |
The present invention provides labeled phospholink nucleotides that can be used in place of naturally occurring nucleotide triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reacti...
|
|
WO/2010/054032A2 |
Methods and apparatus for facilitating the synthesis of compounds in a batch device are presented. Application of the batch type microfluidic devices to the synthesis of radiolabeled compounds is described. These methods and apparatus en...
|
|
WO/2010/049611A1 |
The invention relates to a new type of polysaccharide-block-polypeptide diblock copolymer which is bioresorbable or biodegradable and biocompatible, to a method for preparing same, to the micellar vesicles constituted of this copolymer, ...
|
|
WO/2009/139719A9 |
The present invention relates to novel synthesis routes for preparation of thiodigalactosides of the general formula (12). The method comprises the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corres...
|
|
WO/2010/011312A9 |
This invention provides methods of derivatizing a double-stranded DNA comprising contacting double-stranded DNA with a CpG methyltransf erase and an s-adenosylmethionine analog. This invention also provides methods of sequencing DNA to d...
|
|
WO/2010/040286A1 |
The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2’,3’,5’-tri-O-acetyl-...
|
|
WO/2010/037179A1 |
The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates t...
|
|
WO/2010/038874A1 |
Disclosed are: an anti-XDR-TB agent having excellent pharmacological efficacy against extremely drug-resistant tuberculosis bacteria; an anti-MDR-TB agent having excellent pharmacological efficacy against multi-drug-resistant tuberculosi...
|
|
WO/2010/036698A1 |
The present disclosure describes substituted α-L-bicyclic nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, substituted α-L-bicyclic nucleoside analogs are pro...
|
|
WO/2010/036213A1 |
This invention describes the series of compounds based on the 3-deazaneplanocin A (DZNep) core structure designed to inhibit the function of Polycomb repressive complex 2 (PRC2) proteins.
|
|
WO/2010/036696A1 |
The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclo- hexenyl nucleic acid analogs are provided, having one or...
|
|
WO/2010/031954A1 |
The invention relates to a method for preparing 1,6:2,3-dianhydro-β-D-mannopyranose and is characterized in that it includes a step of cyclizing the compound B, where R is an activating agent, in the presence of a base selected from amo...
|
|
WO/2010/031953A1 |
The invention relates to a method for preparing 1,6:2,3-dianhydro-â-D-mannopyranose and is characterized in that it includes a step of cyclizing the compound C, where R is an alkyl group and R' is an activating agent, in an alcohol/alco...
|
|
WO/2010/029574A2 |
An improved process for preparing gemcitabine or salts thereof, comprising the following steps, dissolved 2-Deoxy-2,2- difluoro-D-ribofuranose-3,5-dibenzoate in an organic solvent and allowed to cool to 0 to 10 degree centigrade temperat...
|
|
WO/2010/028781A1 |
The present invention relates to new 8-substituted (Formula I) and 6, 8-disubstituted 2' -deoxyguano- sines (Formula I) and precursors for preparing these as well as methods for preparing said compounds and precursors. Moreover, the pres...
|
|
WO/2010/026490A1 |
Embodiments of the present disclosure relate generally to reporter compositions which are synthetic nucleotides that comprise nucleotides with a high charge mass moiety attached thereto via a linker molecule. The linker molecules can var...
|
|
WO/2010/027005A1 |
A compound represented by general formula (I) [wherein --- represents a single bond or a double bond; L represents –NH- or the like; X1 represents N or C, provided that in the case where X1 is N, X2 represents C-R and in the case where...
|
|
WO/2010/025566A1 |
The present invention is directed to RNA monomers comprising O-acetal levulinyl protecting groups at the 2' and/or the 5'-hydroxy functionalities of the ribose moiety. Said monomers may be incorporated into oligoribonucleotides or RNA po...
|
|
WO/2010/026153A1 |
Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; wherein R1; R2; R3;Q1and Q2 are as defined herein, processes for their preparation; pharmaceutical compositions containing them and their use in medicine...
|
|
WO/2010/026439A1 |
Single enantionmers of compounds of formula (B), in either the cis or trans configuration, (B) wherein R1 and R2 are as defined herein, can be separated from enantiomeric mixtures thereof by reacting the compound with an acid to produce ...
|
|
WO/2010/025584A1 |
DNA molecule for expressing hairpin RNA, the constructing method and the use thereof are provided. The DNA molecule is a closed circular single-stranded DNA molecule which is constructed by linking four fragments A,B,C and D as following...
|
|
WO/2010/023457A1 |
The invention provides compounds that comprise a 4'-thio nucleoside that is a derivative of 4'-thiothymidine or 4'-thio-2'-deoxyuridine comprising a positron or single photon emitting radioisotope or corresponding non-radioactive isotope...
|
|
WO/2010/021897A1 |
The instant invention provides for novel nucleosidic phosphoramidite crystalline material and crystallization processes for purifying the same, useful for the synthesis of oligonucleotides.
|
|
WO/2010/021344A1 |
Disclosed is a method for preparing a nuclease-resistant nucleic acid, which comprises the steps of mixing a nucleic acid composed of at least three nucleotides, a terminal deoxynucleotide transferase and a 2’,4’-crosslinked nucleosi...
|
|
WO/2010/015637A1 |
This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections.
|
|
WO/2010/017547A1 |
A process of synthesizing a 5-azacytosine nucleoside, such as azacitidine and decitabine, comprises coupling a silylated 5-azacytosine with a protected D-ribofuranose of formula in the presence of a sulfonic acid catalyst.
|
|
WO/2010/017374A1 |
The present invention provides a processes for preparing 5 -Azacytidine, and intermediates thereof, said process Comprising reacting a silylated 5-azacytosine of the formula (II), a sugar moiety having of the formula (III): and a protic ...
|
|
WO/2010/015643A1 |
This invention relates to novel compounds that have various medicinal applications, e.g. for the treatment and/or prevention of viral infections. wherein: X is CH or CR6; R1 is halogen, NR7R8 or OR9; R2 is H, halogen, or NR7R8; R3 is H, ...
|
|
WO/2010/015245A1 |
The invention relates to a method for producing phosphate-bridged nucleoside conjugates. According to the method, a nucleophile is first dissolved in a non-aqueous solvent and dried, and a cyclosaligenyl phosphate compound is subsequentl...
|
|
WO/2010/013442A1 |
Disclosed are: a method for producing a long-chain light-responsive modified nucleic acid without the need of employing any DNA synthesizer; and a light-responsive artificial nucleotide molecule for use in the method. Specifically disclo...
|
|
WO/2010/014134A1 |
Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alon...
|
|
WO/2010/010966A1 |
Disclosed are: a novel nucleoside triphosphate derivative; a nucleic acid probe; a multilabeled nucleic acid probe which enables the detection of a target nucleic acid conveniently and with high sensitivity; a method for producing the mu...
|
|
WO/2010/005986A1 |
The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.
|
|
WO/2010/003540A2 |
The present invention relates to an in-vitro method for the formation of megamitochondria in cells, wherein the cells are grown in a suitable fermentation medium acidulated with lactic acid to pH values between 5.3 and 6.7. The invention...
|
|
WO/2010/002877A2 |
The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.
|
|
WO/2010/000459A1 |
Compounds of formula I: wherein: R2 is hydrogen or C1-C4alkyl; R3 and R4 are hydrogen, -C(=O)R5, or -C(=O)CHR6-NH2; or R3 is hydrogen and R4 is a monophosphate-, diphosphate-, or triphosphate ester; or R3 is hydrogen, -C(=O)CHR5, or -C(=...
|
|
WO/2009/154276A1 |
Disclosed is a process for producing a spiroketal derivative through a compound represented by formula (VI) [wherein the variable groups and the variable numbers are as defined in the description] which can be produced from a dihalobenzy...
|
|
WO/2009/152421A1 |
The present application provides several crystalline forms of gemcitabine base and methods of making the same.
|
|
WO/2009/151921A1 |
Provided herein are methods and compositions for nucleic acid amplification. These methods involve the use of 3'-substituted nucleoside 5'-triphosphates or 3'-substituted terminated primers in nucleic acid amplification reactions. In cer...
|
|
WO/2009/152353A2 |
The present invention relates generally to labeled and unlabled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides ...
|
|
WO/2009/152431A1 |
The invention provides P2Y1 receptor antagonists of Formula (I); wherein R1-R3 are as defined in the specification, pharmaceutical compositions comprising the same, and the use of such antagonists in the treatment of a disease or conditi...
|
|
WO/2009/144418A1 |
The invention relates to a method for the chemical synthesis of RNA, comprising the following steps: a) bonding to a solid support of a monomer having formula (II) in which - X1 is a dimethoxytrityl group, - X6 is H or an OAc group or OX...
|
